FDA calendar · February 2021 · built from SEC filings

PDUFA dates February 2021: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in February 2021. The FDA calendar also recorded 17 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in February 2021

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

February 2021: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
February 1, 2021Orilissa (elagolix sodium)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
February 1, 2021Cefazolin In Dextrose (cefazolin sodium)BAXLabel expansion—ApprovedopenFDA Drugs@FDA
February 1, 2021Aria® (golimumab)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
Feb 2021Month disclosedYCANTH (cantharidin)VRCANDA/BLA accepted—Completedsec_424b
February 5, 2021Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
February 9, 2021Botox Cosmetic (onabotulinumtoxina)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
February 9, 2021Zirabev (bevacizumab-bvzr)PFELabel expansion—ApprovedopenFDA Drugs@FDA
February 9, 2021Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
February 11, 2021Evkeeza (evinacumab-dgnb)REGNFDA approval—ApprovedopenFDA Drugs@FDA
February 16, 2021Entresto (sacubitril; valsartan)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
February 19, 2021Imfinzi® (durvalumab)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
February 22, 2021Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
February 24, 2021AMJEVITA® (adalimumab)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
February 24, 2021Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
February 26, 2021Repatha (evolocumab)AMGNFDA approval—ApprovedopenFDA Drugs@FDA
February 26, 2021Defencath (heparin sodium; taurolidine)CRMDComplete Response Letter—CRL issuedFDA Complete Response Letters

February 2021: dated readouts

No events in this view.

February 2021: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Feb 2021Month discloseddeucrictibant (PHA121)PHVSTrial startHAE in December 2022CompletedSEC 8-K Exhibit 99.1

Questions

What PDUFA dates are in February 2021?

0 PDUFA dates fell in February 2021. The FDA calendar also recorded 17 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.